Atara Biotherapeutics, Inc. announced the appointment of Ameet Mallik to the Board of Directors. Mr. Mallik is a biotechnology and pharmaceutical industry expert with a successful track record of bringing innovative oncology therapeutics, including CAR T cell therapy, to market in the U.S. and other countries. With more than 25 years of experience, Mr. Mallik adds relevant and directly applicable management and operational experience that will be instrumental as Atara progresses toward commercial launch of its lead product, tab-cel®. Ameet Mallik is Chief Executive Officer of Rafael Holdings, a late-stage cancer metabolism therapeutic company and has held several leadership roles at Novartis Oncology, most recently as Executive Vice President and Head of U.S. Oncology where he was responsible for commercial and medical oncology operations. Before leading U.S. Oncology, Mr. Mallik served as the Global Head, Marketing, Value and Access as well as Head, Latin America and Canada, both for Novartis Oncology.